Navigation Links
Are New Chemo Treatments Cost-Effective?
Date:3/16/2010

Drug advances extend lives, but one study puts cost per life-year gained at about $66,200

TUESDAY, March 16 (HealthDay News) -- New chemotherapy agents for metastatic colon cancer improve patient survival but are costly, says a new study.

Researchers at Emory University in Atlanta analyzed data from 4,665 patients, aged 66 and older, diagnosed with metastatic colon cancer between 1995 and 2005. Compared to those who received older chemotherapy agents, patients who received one or more of the six chemotherapy agents approved in the United States between 1996 and 2004 lived an average of 6.8 months longer.

That increase in survival was associated with a lifetime cost increase of $37,100, which equates to $66,200 per year of life gained. After they made additional adjustments, the researchers calculated that the cost for each quality-adjusted life-year (a year of life in perfect health) gained was $99,100.

The study was published in the March 16 online edition of the journal Archives of Internal Medicine.

"New chemotherapeutic agents for colorectal cancer have been singled out as examples of high-cost/low-value medical care; no doubt they are the types of therapies that would receive close scrutiny if Medicare and other payers were to consider cost-effectiveness in coverage decisions," wrote David H. Howard and colleagues.

"Our estimate of the cost per quality-adjusted life-year gained, $100,000, is below most estimates of the willingness to pay for a life-year. However, continuation of Medicare's open-ended coverage policy for new chemotherapeutic agents and other expensive technologies will prove difficult to sustain as costs for the program continue to rise," they concluded.

More information

The American Cancer Society has more about colorectal cancer.



-- Robert Preidt



SOURCE: JAMA/Archives journals, news release, March 16, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Older Colon Cancer Patients Less Likely to Get Chemo
2. Study evaluates costs and benefits of new chemotherapy drugs
3. Scientists identify microRNA as possible cause of chemotherapy resistance
4. Roche/Genentech/Chugais Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer
5. New developments in nanotechnology tackle the 2 biggest problems associated with chemotherapy
6. Patients with resectable esophageal adenocarcinoma benefit from neoadjuvant chemoradiotherapy
7. Breast cancer multigene test helping patients avoid chemotherapy
8. Stem Cells Might Reverse Heart Damage From Chemo
9. Herb May Counter Liver Damage From Chemo
10. Mayo Clinic researchers say breast cancer survival improves Herceptin used with chemotherapy
11. Chemo With Herceptin May Be Best for Some Breast Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... August 18, 2017 , ... ... at creating a transparent, verifiable database to help the cannabis industry move towards ... Paragon hopes to deliver a faster technology with lower fees. Paragon will build ...
(Date:8/19/2017)... ... August 19, 2017 , ... Praeclarus Press has ... These illustrations show the diversity of the breastfeeding mothers, using bright colors ... of sizes. These illustrations are also available on tote bags, notepads, smartphone cases, ...
(Date:8/19/2017)... ... August 19, 2017 , ... “Congratulations! It's A Boy! ... children to both their parents and God. “Congratulations! It's A Boy! God’s Gift: A ... a couple from Long Island, New York. , Published by Christian Faith Publishing, Dale ...
(Date:8/18/2017)... York, New York (PRWEB) , ... ... ... International Courier, LLC, d/b/a Quick International, LLC (“Quick”), a highly specialized asset-light ... announced it has entered into a definitive agreement to purchase Unitrans International ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... devices. Through an educational webinar, they will present the line of epMotion automated ... learn how easy you can automate everyday pipetting tasks. , Ideal for scientists ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc (NASDAQ: ... agreements to resolve virtually all known U.S. mesh product ... to resolve the known remaining U.S. claims at reasonable ... beginning in the fourth quarter of 2017 and continuing ... its second quarter 2017 results, the Company intends to ...
(Date:8/2/2017)... Calif. , Aug. 2, 2017 ... Continental Who,s Who as a Pinnacle Lifetime Professional ... the Key Account Manager at Turing Pharmaceuticals, AG. ... negotiations, troubleshooting and relationship building.                ... has more than 25 years of experience as ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
Breaking Medicine Technology: